Clinical, endocrine, and molecular findings in 17β-hydroxysteroid dehydrogenase type 3 deficiency

Journal of Endocrinological Investigation

Volumn 31, Issue 1, 2008, Pages 85-91

  Faienza, M F ^a   Giordani, L ^a   Delvecchio, M ^a   Cavallo, Luci ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

17 hydroxysteroid dehydrogenase type 3 deficiency; 17 hydroxysteroid dehydrogenases; Androgens; Disorders of sex development; Gene mutations

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTENEDIONE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE; STEROID HORMONE; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 3; UNCLASSIFIED DRUG;

ANDROGEN INSENSITIVITY SYNDROME; CATALYSIS; CHROMOSOME 9Q; CLINICAL FEATURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY INTERVENTION; ENZYME DEFICIENCY; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GONADECTOMY; HORMONAL THERAPY; HORMONE SYNTHESIS; HUMAN; KARYOTYPE 46,XY; LEYDIG CELL; MULTIGENE FAMILY; MUTATIONAL ANALYSIS; PATHOPHYSIOLOGY; PREPUBERTY; REVIEW; STEROIDOGENESIS; TESTOSTERONE 17BETA DEHYDROGENASE 3 DEFICIENCY; VIRILIZATION;

EID: 40949154384     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345572     Document Type: Review

References (51)

1. Baulieu EE. Neurosteroids: a new function in the brain. Biol Cell 1991, 71: 3-10.
2. Labrie F. Intracrinology. Mol Cell Endocrinol 1991, 78: C113-8.
3. Labrie F, Luu-The V, Lin SX, et al. Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 2000, 25: 1-16.
4. Labrie F, Bélanger A, Luu-The V, et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 1998, 63: 322-8.
5. Stewart PM, Sheppard MC. Novel aspects of hormone action: intracellular ligand supply and its control by a series of tissue specific enzymes. Mol Cell Endocrinol 1992, 83: C13-8.
6. Lee PA, Houk CP, Ahmed SF, Hughes IA. International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 2006, 118: 488-500.
7. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004, 25: 947-70.
8. Hoppe U, Holterhus PM, Wünsch L, et al. Tissue-specific transcription profiles of sex steroid byosinthesis enzymes and the androgen receptor. J Mol Med 2006, 84: 651-9.
9. Khan N, Sharma KK, Andersson S, Auchus RJ. Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells. Arch Biochem Biophys 2004, 429: 50-9.
10. Andersson S. Molecular genetics of androgenic 17 beta-hydroxysteroid dehydrogenases. J Steroid Biochem Mol Biol 1995, 55: 533-4.
11. Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat Genet 1994, 7: 34-9.
12. Xiaofei D, Rosenfeld RL, Quin K. Molecular mechanisms regulating basal espression of the human 171β-hydroxy steroid dehydrogenase type 3 (HSD17B3) gene promoter in Leydig cells. In: Endocrine 2006, Boston, P1-372.
13. Andersson S, Geissler WM, Wu L, et al. Molecular genetics and pathophysiology of 17 beta-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab 1996, 81: 130-6.
14. Griffin JE, Wilson EM. Disorders of sexual differentiation. In: Walsh PC, Resnik AB, Stamey TA, Vaughan ED Jr, eds. Campbell's textbook of urology Philadelphia: WB Saunders, 1992: 1509-42.
15. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995, 16: 271-321.
16. Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha-reductase 2 deficiency. Endocr Rev 1993, 14: 577-93.
17. Gobinet J, Poujol N, Sultan Ch. Molecular action of androgens. Mol Cell Endocrinol 2002, 198: 15-24.
18. Miller WL, Huang N, Pandey AV, Flück CE, Agrawal V. P450 oxidoreductase deficiency: a new disorder of steroidogenesis. Ann N Y Acad Sci 2005, 1061: 100-8.
19. Noguchi K, Saito K. [Disorder of androgen biosynthesis]. Nippon Rinsho 2004, 62: 339-43.
20. Saez JM, De Peretti E, Morera AM, David M, Bertrand J. Familial male pseudohermaphroditism with gynecomastia due to a testicular 17-ketosteroid reductase defect. I. Studies in vivo. J Clin Endocrinol Metab 1971, 32(5): 604-10.
21. Grumbach MM, Shaw EB. Further studies on the treatment of congenital adrenal hyperplasia with cortisone: IV. Effect of cortisone and com pound B in infants with disturbed electrolyte metabolism, by John F. Crigler Jr, MD, Samuel H. Silverman, MD, and Lawson Wilkins, MD, Pediatrics, 1952, 10: 397-413. Pediatrics 1998, 102: 215-21.
22. Can S, Zhu YS, Cai LQ, et al. the identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred. J Clin Endocrinol Metab 1998, 83: 560-9.
23. Eckstein B, Cohen S, Farkas A, Rösler A. The nature of the defect in familial male pseudohermaphroditism in Arabs of Gaza. J Clin Endocrinol Metab 1989, 68: 477-85.
24. Ulloa-Aguirre A, Bassol S, Poo J, et al. Endocrine and biochemical studies in a 46,XY phenotypically male infant with 17-ketosteroid reductase deficiency. J Clin Endocrinol Metab 1985, 60: 639-43.
25. Balducci R, Toscano V, Wright F, et al. Familial male pseudohermaphroditism with gynaecomastia due to 17 beta-hydroxysteroid dehydrogenase deficiency. A report of 3 cases. Clin Endocrinol (Oxf) 1985, 23: 439-44.
26. Mendonca BB, Inacio M, Arnhold IJ, et al. Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 2000, 79: 299-309.
27. Rogers DG, Chasalow FI, Blethen SL. Partial deficiency in 17-ketosteroid reductase presenting as gynecomastia. Steroids 1985, 45: 195-200.
28. Castro-Magana M, Angulo M, Uy J. Male hypogonadism with gynecomastia caused by late-onset deficiency of testicular 17-ketosteroid reductase. N Engl J Med 1993, 328: 1297-301.
29. Pang SY, Softness B, Sweeney WJ 3rd, New MI. Hirsutism, polycystic ovarian disease, and ovarian 17-ketosteroid reductase deficiency. N Engl J Med 1987, 316: 1295-301.
30. Rösler A, Silverstein S, Abeliovich D. A (R80Q) mutation in 17 beta-hydroxysteroid dehydrogenase type 3 gene among Arabs of Israel is associated with pseudohermaphroditism in males and normal asymptomatic females. J Clin Endocrinol Metab 1996, 81: 1827-31.
31. Mendonca BB, Arnhold IJ, Bloise W, Andersson S, Russell DW, Wilson JD. 17Beta-hydroxysteroid dehyclrogenase 3 deficiency in women. J Clin Endocrinol Metab 1999, 84: 802-4.
32. Saez JM, Morera AM, De Peretti E, Bertrand J. Further in vivo studies in male pseudohermaphroditism with gynecomastia due to a testicular 17-ketosteroid reductase defect (compared to a case of testicular feminization). J Clin Endocrinol Metab 1972, 34: 598-600.
33. Imperato-McGinley J, Peterson RE, Stoller R, Goodwin WE. Male pseudohermaphroditism secondary to 17 beta-hydroxysteroid dehydrogenase deficiency: gender role change with puberty. J Clin Endocrinol Metab 1979, 49: 391-5.
34. Goebelsmann U, Horton R, Mestman JH, et al. Male pseudohermaphroditism due to testicular 17β-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 1973, 36: 867-79.
35. Martel C, Rhéaume E, Takahashi M, et al. Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J Steroid Biochem Mol Biol 1992, 41: 597-603.
36. Luu The V, Lachance Y, Labrie C, et al. Full length cDNA structure and deduced amino acid sequence of human 3 beta-hydroxy-5-ene steroid dehydrogenase. Mol Endocrinol 1989, 3: 1310-2.
37. Rosler A. 17β-hydroxysteroid dehydrogenase 3 deficiency in the Mediterranean population. Pediatric Endocrinology Reviews 2006, 3 (suppl 3): 455-61.
38. Van Poucke C, Van de Velde M, Van Peteghem C. Combination of liquid cromatography/tandem mass spectrometry and gas cromatography/mass spectrometry for the detection of 21 anabolic steroid residues in bovine urine. J Mass Spectrom 2005, 40: 731-8.
39. Rösler A, Bélanger A, Labrie F. Mechanisms of androgen production in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 1992, 75: 773-8.
40. Bilbao JR, Loridan L, Audí L, Gonzalo E, Castaño L. A novel missense (R80W) mutation in 17-beta-hydroxysteroid dehydrogenase type 3 gene associated with male pseudohermaphroditism. Eur J Endocrinol 1998, 139: 330-3.
41. Lindqvist A, Hughes IA, Andersson S. Substitution mutation C268Y causes 17 beta-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab 2001, 86: 921-3.
42. Moghrabi N, Hughes IA, Dunaif A, Andersson S. Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3). J Clin Endocrinol Metab 1998, 83: 2855-60.
43. Boehmer AL, Brinkmann AO, Sandkuijl LA, et al. 17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab 1999, 84: 4713-21.
44. Twesten W, Holterhus P, Sippell WG, et al. Clinical, endocrine, and molecular genetic findings in patients with 17beta-hydroxysteroid dehydrogenase deficiency. Horto Res 2000, 53: 26-31.
45. Bachelot A, Chakhtoura Z, Kuttenn F, Morel Y, Touraine PH. 17 beta hydroxysteroid dehydrogenase deficiency cause by homozygous h271r mutation. In: Endocrine 2006, Boston. p. P156.
46. Faienza MF, Giordani L, Acquafredda A, et al. 46,XY caused by a rare mutation of the 17-β-hydroxysteroid dehydrogenase deficiency type 3 gene. IJP 2007, 33: 13-6.
47. Margiotti K, Kim E, Pearce CL, Spera E, Novelli G, Reichardt JK. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 2002, 53: 65-8.
48. Hiort O, Reinecke S, Thyen U, et al. Puberty in disorders of somatosexual differentiation. J Pediatr Endocrinol Metab 2003, 16 (Suppl 2): 297-306.
49. Saggese G, Bertelloni S, Navari S, Bertacca L, Geraci S. [Neonate with ambiguous genitalia: medical therapy after the first weeks of life]. Minerva Pediatr 2003, 55 (Suppl 1): 58-62.
50. Farkas A, Rosler A. Ten years experience with masculinizing genitoplasty in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency. Eur J Pediatr 1993, 152 (Suppl 2): S88-90.
51. Wilson JD. The role of androgens in male gender role behavior. Endocr Rev 1999, 20: 726-37.